# A Study to Evaluate Safety and Efficacy of BEY1107 in Combination with Capecitabine in Patients with Metastatic Colorectal Cancer

Source: https://onco.cc/trials/nct05093907/  
OnCo record `nct05093907` (Trial). Data CC BY-NC 4.0, attribute "Data from OnCo (onco.cc)"; commercial use needs a licence.

## TL;DR

A phase 1/2 trial of Capecitabine in colorectal cancer, run by BeyondBio Inc., now recruiting.

## Summary

A Study to Evaluate Safety and Efficacy of BEY1107 in Combination with Capecitabine in Patients with Metastatic Colorectal Cancer is a phase 1/2 interventional study registered as NCT05093907 by BeyondBio Inc., with 27 participants planned, started 2021-08-31 and due to reach its primary completion in 2026-11-30. Interventions recorded: BEY1107, Capecitabine. Conditions listed: Metastatic Colorectal Cancer. No results are recorded here; the registry entry is the source.

## Fields

- Kind: Trial
- Status: recruiting
- Last checked: 2026-09-16
- Tags: ctgov-ingest
- Registry id: NCT05093907
- Phase: 1/2
- Setting: An Open-label, Single Center, Phase I/II Clinical Trial to Assess the Maximum Tolerated Dose, Safety and Efficacy of BEY1107 in Combination with Capecitabine in Patients with Metastatic Colorectal Cancer Refractory or Intolerant to Standard of Care
- Sponsor: BeyondBio Inc.
- Enrolled: 27

## Sources

- ClinicalTrials.gov NCT05093907: https://clinicaltrials.gov/study/NCT05093907

## Connected records

- cancers: [Colorectal cancer](https://onco.cc/cancers/colorectal/)
- drugs: [Capecitabine](https://onco.cc/drugs/capecitabine/)

---
JSON: https://onco.cc/api/v1/entities/nct05093907.json